Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB-0,59
PKN60,9560,98-0,67
Msft431,45431,56-0,89
Nokia3,75053,7995-0,41
IBM215,06215,130,44
Mercedes-Benz Group AG57,5357,550,77
PFE29,7429,75-0,26
18.09.2024 21:49:54
Indexy online
AD Index online
select
AD Index online
 

  • 18.09.2024 17:35:16
DBV Technologies (Paris)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
0,72 -1,50 -0,01 41 055
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 18.09.2024
Popis společnosti
Obecné informace
Název společnostiDBV Technologies SA
TickerDBV
Kmenové akcie:Ordinary Shares
RICDBV.PA
ISINFR0010417345
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 30.06.2024 106
Akcie v oběhu k 30.06.2024 96 270 090
MěnaUSD
Kontaktní informace
UliceBatiment IRO, 107 Av. de la Republique
MěstoCHATILLON
PSČ92320
ZeměFrance
Kontatní osobaKatie Matthews
Funkce kontaktní osobyInvestor Relations
Telefon33 155 427 878
Fax33143261083
Kontatní telefon18 575 292 563

Business Summary: DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Financial Summary: BRIEF: For the six months ended 30 June 2024, DBV Technologies SA revenues decreased 43% to $2.6M. Net loss applicable to common stockholders increased 35% to $60.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects R&D Costs - Other increase of 46% to $34M (expense), Personnel Charges increase from $2.6M to $8.8M (expense).
Odvětvová klasifikace
TRBC2012Proprietary & Advanced Pharmaceuticals
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations



  • Poslední aktualizace: 18.09.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorDaniel Tasse6405.03.201916.11.2018
Chief Financial OfficerVirginie Boucinha5406.11.202306.11.2023
Chief Medical OfficerPharis Mohideen5922.07.201922.07.2019
Chief Regulatory OfficerRobert Pietrusko7507.05.202407.05.2024